Literature DB >> 16449126

Comparing three screening strategies for combining first- and second-trimester Down syndrome markers.

Glenn E Palomaki1, Klaus Steinort, George J Knight, James E Haddow.   

Abstract

OBJECTIVE: To describe the choices and tradeoffs inherent in 3 published strategies that combine first- and second-trimester markers for Down syndrome screening.
METHODS: Published marker distributions for Down syndrome and unaffected pregnancies in the first and second trimesters were combined with a maternal age distribution and age-associated Down syndrome risk in a statistical model to compare sequential, contingent, and integrated screening.
RESULTS: Sequential and contingent screening strategies are always less efficient (higher false-positive rate for a given detection rate) than integrated screening, but the reduction in efficiency is dependent on the combination of risk cutoffs chosen. At a fixed false-positive rate, sequential and contingent strategies perform better when a higher proportion of the false positives occur in the second trimester. For all 3 strategies, increasing the overall false-positive rate from 2% to 5% increases detection (from approximately 85% to 91%). Although associated with reduced screening efficiency compared with integrated screening, both sequential and contingent screening identify the majority of detected Down syndrome cases early. With contingent screening, the process is also completed in the first trimester for most women.
CONCLUSION: Integrated screening is the most efficient of the 3 strategies, but it is possible to select risk cutoffs for both sequential and contingent strategies that minimize losses in efficiency while maintaining early detection and early completion. For all of these strategies, well-designed intervention trials are needed to determine acceptability to women and providers in primary care settings and to assess real-world performance. LEVEL OF EVIDENCE: III.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449126     DOI: 10.1097/01.AOG.0000195061.48747.f4

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Optimising prenatal diagnosis of Down's syndrome.

Authors:  James P Neilson; Zarko Alfirevic
Journal:  BMJ       Date:  2006-02-25

Review 2.  Noninvasive prenatal testing: the future is now.

Authors:  Errol R Norwitz; Brynn Levy
Journal:  Rev Obstet Gynecol       Date:  2013

3.  Alzheimer's disease: diagnostics, prognostics and the road to prevention.

Authors:  Iris Grossman; Michael W Lutz; Donna G Crenshaw; Ann M Saunders; Daniel K Burns; Allen D Roses
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

4.  NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy.

Authors:  K L Wilson; J L Czerwinski; J M Hoskovec; S J Noblin; C M Sullivan; A Harbison; M W Campion; K Devary; P Devers; C N Singletary
Journal:  J Genet Couns       Date:  2012-11-22       Impact factor: 2.537

5.  How can we improve amniocentesis decision-making?

Authors:  Lisa Soleymani Lehmann
Journal:  Isr J Health Policy Res       Date:  2016-02-05

6.  Correlation of pregnancy outcome with quadruple screening test at second trimester.

Authors:  Shahla Yazdani; Rahele Rouholahnejad; Nesa Asnafi; Majid Sharbatdaran; Marziihe Zakershob; Zinatossadat Bouzari
Journal:  Med J Islam Repub Iran       Date:  2015-10-19

7.  A proof-of-concept study on the effects of low total cfDNA content and solutions to increase the NIPT trisomy 21 detection rate.

Authors:  Yang Du; Ailing Chen; Rui Yang; Tao Zhou; Qin Zhou; Lan Yang; Juan Wang; Yan Hong; Chen Chen; Qian Wan; Lin Yang; Ying Chen
Journal:  J Clin Lab Anal       Date:  2019-09-30       Impact factor: 2.352

8.  Prediction, prevention and personalisation of medication for the prenatal period: genetic prenatal tests for both rare and common diseases.

Authors:  Munis Dundar; Asli Subasioglu Uzak; Murat Erdogan; Yagut Akbarova
Journal:  EPMA J       Date:  2011-05-06       Impact factor: 6.543

9.  Screening for fetal aneuploidy and neural tube defects.

Authors:  Deborah A Driscoll; Susan J Gross
Journal:  Genet Med       Date:  2009-11       Impact factor: 8.822

10.  Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation.

Authors:  Jean Gekas; Geneviève Gagné; Emmanuel Bujold; Daniel Douillard; Jean-Claude Forest; Daniel Reinharz; François Rousseau
Journal:  BMJ       Date:  2009-02-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.